Posted by Michael Wonder on 23 Mar 2021
Health Canada approves Kesimpta, the first and only self-administered targeted B-cell therapy for relapsing remitting multiple sclerosis
23 March 2021 - Approval is based on two Phase 3 studies (ASCLEPIOS I & II) demonstrating significant reductions in risk of relapses, confirmed disability worsening and MRI lesions.
Novartis Pharmaceuticals Canada is pleased to announce that Health Canada has approved Kesimpta (ofatumumab) for the treatment of adults with relapsing remitting multiple sclerosis with active disease defined by clinical and imaging features.
